Presidio Pharma Raises $27 Million
Presidio Pharmaceuticals Inc., a San Francisco-based drug company focused on small-molecule compounds to treat HIV-1, HCV and other chronic viral infections, has raised $27 million in additional Series B funding. The round now stands at $53 million. New Leaf Venture Partners was joined on the tranche by return backers Panorama Capital, Baker Brothers Investments, Ventures West Capital, Bay City Capital, Nexus Medical Partners and Sagamore BioVentures.
10 July 2009•2 mins read
